Effect of Low-Dose Supplementation of Arginine Vasopressin on Need for Blood Product Transfusions in Patients With Trauma and Hemorrhagic Shock: A Randomized Clinical Trial

What Was Tested

Researchers studied Vasopressin in this randomized controlled trial publication.

Current therapies for traumatic blood loss focus on hemorrhage control and blood volume replacement.

Who Took Part

By PubMed's age tags, the people studied were teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

Exclusion criteria consisted of prehospital cardiopulmonary resuscitation, emergency department thoracotomy, corticosteroid use, chronic renal insufficiency, coronary artery disease, traumatic brain injury requiring any neurosurgical intervention, pregnancy, prisoner status, or AVP administration before enrollment.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Vasopressin and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Vasopressin.

A placebo (an inactive look-alike) gave the Vasopressin group a baseline to be compared against.

Data were analyzed from May 1, 2013, through May 31, 2017, using intention to treat and per protocol.

What Was Measured

Topics PubMed links to this paper include Arginine Vasopressin, Blood Component Transfusion, Clinical Protocols, Hemostatics, Shock, Hemorrhagic, Trauma Centers and Wounds and Injuries.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vasopressin.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (JAMA surgery), a journal based in United States.

More context: the Vasopressin compound page.